ArticleScience advances2024

Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors.

Chiho Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.